Delivery Order SPE2DB22D1002-SPE2DB24FKYS0
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,578,946 units of VYVANSE 30 MG CAPSULES 100S. The $1,789.44 contract has a completion date of February 7, 2024. Amerisourcebergen Drug Corp is the prime contractor and holds an indefinite delivery contract (IDC) with a potential value of $999,999,999.00 from DLA for the delivery of pharmaceutical products and medical...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the delivery of VYVANSE 30 mg capsules. The contract has a potential value of $1,563.77 and a completion date of February 23, 2024. Amerisourcebergen Drug Corp is the prime contractor, and the contract was awarded without any set-aside designation. In addition to this specific delivery order, Amerisourcebergen Drug Corp...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,564,183,166 units of VYVANSE 30 MG CAPSULE 100S. The contract has a ceiling value of $2,155.00 and an ultimate completion date of April 8, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract with DLA valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,403.54 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is to provide 4,564,015,246 units of the drug VYVANSE 30 MG CAPSULE 100S. This delivery order is part of a larger, single-award indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp, valued at up to $999,999,999.00 and running through December 31, 2025. The IDC serves as the...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of VYVANSE 20 MG CAPSULE 100S. The total ceiling value of the contract is $1,535.33 and the ultimate completion date is April 8, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp with a potential value of up to $999,999,999.00 and a...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 100 units of the prescription medication VYVANSE 50 MG CAPSULE. The $5,413.84 contract has a completion date of February 27, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which does not have a set-aside designation. Amerisourcebergen Drug Corp also holds an Indefinite Delivery Contract (IDC)...
- The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,647,521 units of VYVANSE 30 mg capsules. The $5,470.48 contract, awarded on February 13, 2024, has a completion date of February 14, 2024 and does not use any set-aside designation. Amerisourcebergen Drug Corp, as the prime contractor, will fulfill this order...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,471,651 units of the prescription drug VYVANSE 30 MG CAPSULE. The order has a total potential value of $2,373.57 and a completion date of January 26, 2024. Amerisourcebergen Drug Corp is the prime contractor for this award, which is not designated as a set-aside contract. This delivery order is part of a larger indefinite...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the provision of 4,563,618,549 units of the prescription medication VYVANSE 30 MG CAPSULE. The order, valued at $6,488.84, has a completion date of February 12, 2024. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up to $999,999,999.00 and running through December 31, 2025,...
- The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 4,563,743,165 units of the pharmaceutical product VYVANSE 40 MG CAPSULE 100S. The $1,724.00 contract has a completion date of February 23, 2024 and was awarded on February 22, 2024. Amerisourcebergen Drug Corp is the prime contractor for this order, which is not associated with a set-aside designation....
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB24FKYS0Delivery Order
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a firm fixed price delivery order contract valued at $1,049.90 to provide VYVANSE 30 MG CAPSULE 100S. This contract does not have a set-aside designation and is scheduled for completion on March 1, 2024. Amerisourcebergen Drug Corp, a for-profit organization, is the prime contractor and is responsible for delivering the pharmaceutical product to support military treatment programs and facilities. This award is associated with a larger indefinite delivery contract (IDC) held by Amerisourcebergen Drug Corp with DLA, valued at up to $999,999,999.00 and with a performance period through December 31, 2025. The IDC serves as the primary contract vehicle for Amerisourcebergen to provide a comprehensive range of medications and healthcare materials to DLA Troop Support Medical facilities supporting the Department of Defense.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 2/29/24 |